ACADIA PHARMACEUTICALS INC. Investment Income, Net
ACADIA PHARMACEUTICALS INC. (ACAD) reported Investment Income, Net of $41.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-07.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2013-05-07
- ACADIA PHARMACEUTICALS INC. investment income, net for the quarter ending 2013-03-31 was $41.00K, a 215.38% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. investment income, net for the quarter ending 2012-12-31 was $9.00K, a 35.71% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. investment income, net for the quarter ending 2012-09-30 was $5.00K, a 70.59% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. investment income, net for the quarter ending 2012-06-30 was $10.00K, a 64.29% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. investment income, net for fiscal 2012 was $37.00K, a 57.47% decline from fiscal 2011.
- ACADIA PHARMACEUTICALS INC. investment income, net for fiscal 2011 was $87.00K, a 93.33% increase from fiscal 2010.
- ACADIA PHARMACEUTICALS INC. investment income, net for fiscal 2010 was $45.00K, a 86.07% decline from fiscal 2009.
- ACADIA PHARMACEUTICALS INC. investment income, net for fiscal 2009 was $323.00K.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2013-03-31 | $41.00K 10-Q · filed 2013-05-07 | $50.00K derived: sum of 2 quarters · filed 2013-05-07 | $55.00K derived: sum of 3 quarters · filed 2013-05-07 | $65.00K derived: sum of 4 quarters · filed 2013-05-07 |
| 2012-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $14.00K derived: sum of 2 quarters · filed 2013-03-12 | $24.00K derived: sum of 3 quarters · filed 2013-03-12 | $37.00K 10-K · filed 2013-03-12 |
| 2012-09-30 | $5.00K 10-Q · filed 2012-11-05 | $15.00K derived: sum of 2 quarters · filed 2012-11-05 | $28.00K 10-Q · filed 2012-11-05 | $42.00K derived: sum of 4 quarters · filed 2013-05-07 |
| 2012-06-30 | $10.00K 10-Q · filed 2012-08-08 | $23.00K 10-Q · filed 2012-08-08 | $37.00K derived: sum of 3 quarters · filed 2013-05-07 | $54.00K derived: sum of 4 quarters · filed 2013-05-07 |
| 2012-03-31 | $13.00K 10-Q · filed 2013-05-07 | $27.00K derived: sum of 2 quarters · filed 2013-05-07 | $44.00K derived: sum of 3 quarters · filed 2013-05-07 | $72.00K derived: sum of 4 quarters · filed 2013-05-07 |
| 2011-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $31.00K derived: sum of 2 quarters · filed 2013-03-12 | $59.00K derived: sum of 3 quarters · filed 2013-03-12 | $87.00K 10-K · filed 2013-03-12 |
| 2011-09-30 | $17.00K 10-Q · filed 2012-11-05 | $45.00K derived: sum of 2 quarters · filed 2012-11-05 | $73.00K 10-Q · filed 2012-11-05 | |
| 2011-06-30 | $28.00K 10-Q · filed 2012-08-08 | $56.00K 10-Q · filed 2012-08-08 | ||
| 2010-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $27.00K derived: sum of 2 quarters · filed 2013-03-12 | $35.00K derived: sum of 3 quarters · filed 2013-03-12 | $45.00K 10-K · filed 2013-03-12 |
| 2010-09-30 | $15.00K 10-Q · filed 2011-11-09 | $23.00K derived: sum of 2 quarters · filed 2011-11-09 | $33.00K 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $8.00K 10-Q · filed 2011-08-10 | $18.00K 10-Q · filed 2011-08-10 | ||
| 2009-12-31 | $323.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |